Possible clinical efficacy and tolerability of platelet-rich plasma in the treatment of patients with recalcitrant plane warts: The first clinical study.

Abstract

Plane warts are prevalent cutaneous diseases, caused by different serotypes of human papillomavirus. This study aimed to assess the possible clinical efficacy and tolerability of platelet-rich plasma (PRP) in the treatment of patients with multiple recalcitrant plane warts. This prospective cohort clinical study was carried out on 25 patients with clinical and dermoscopic evident multiple recalcitrant plane warts. The patients were treated with autologous intralesional PRP injections every month until a complete clearance or for a maximum of two sessions. Then, patients were clinically evaluated one month after every session and after a six-month follow-up from the last injection. Of the included patients, 20 (80%) patients had facial plane warts, 3 (12%) patients had plane warts in the dorsum of hands, and 2 (8%) patients had plane warts in the dorsal aspect of feet. 60% of the patients have more than 100 plane warts, and all the patients had plane warts than 1cm in size. The complete improvement was observed in 20% and 100% of the patients after the first and second sessions, respectively. No recurrence was detected after a six-month follow-up. No side effects were recorded after the treatment sessions. Intralesional injection of PRP could be potentially effective and well-tolerated immunotherapy for the treatment of multiple recalcitrant plane warts. Whatever, more studies are needed with a larger sample size and a longer period of follow-up. Also, randomized and controlled studies are required to evaluate its efficacy in treating different clinical types of warts.